Celsion’s Immunotherapy Candidate Impresses, Stock Surges – Zacks.com
|
Celsion's Immunotherapy Candidate Impresses, Stock Surges
Zacks.com Celsion Corporation (CLSN – Free Report) announced results from phase Ib study — OVATION — evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. Celsion is developing the candidate for newly … |
